IgM-Enriched Immunoglobulin Adjunctive Therapy for Severe Pneumonia

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

There is an unmet medical need for improved methods to treat Severe Community Acquired Pneumonia (sCAP) to reduce morbidity and mortality and allow earlier weaning from invasive mechanical ventilation, as current treatments are ineffective in improving patient outcomes despite advances in antibiotics.

Innovation Solution

A human IgM-enriched immunoglobulin preparation, not chemically modified with beta-propiolactone, is used as an adjunctive treatment for sCAP, which is plasma-derived and enriched in IgM, IgA, and IgG, with specific dosing schemes and biomarker-based patient selection to identify subgroups that benefit most from the treatment.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Adaptability or versatility

If broad-spectrum antibiotics are used to treat sCAP, then the range of pathogens covered is improved, but mortality and morbidity remain high and do not improve

Engineering Contradiction:

Improvepathogen coverageVSAvoidmortality reduction

Core Design Contradiction:

Adaptability or versatilityVSReliability

Solution Approach 1:

The patent combines broad-spectrum antibiotics with IgM-enriched immunoglobulin preparation to create a synergistic treatment approach. The immunoglobulin preparation contains multiple antibody classes (IgM, IgG, IgA) that work together to provide both direct antimicrobial activity and immunomodulatory effects, addressing the limitation of antibiotics alone in reducing mortality despite broad pathogen coverage

Inventive Principle:

Principle #5Merging (Combining)

Solution Approach 2:

The treatment uses a composite therapeutic approach combining pharmacological (antibiotics) and immunological (immunoglobulin) agents. The immunoglobulin preparation itself is a composite of different antibody types and concentrations, specifically enriched in IgM (10-40% of total immunoglobulin content), creating a multi-component therapy that addresses both infection control and immune system support

Inventive Principle:

Principle #40Composite materials

2Ease of operation

If IgG preparations are used to treat sepsis, then treatment is simplified, but clinical studies show negative results and the guideline does not recommend their use

Engineering Contradiction:

Improvetreatment simplicityVSAvoidclinical effectiveness

Core Design Contradiction:

Ease of operationVSReliability

Solution Approach 1:

The patent changes the key parameter from IgG-only preparation to IgM-enriched preparation (10-40% IgM content). This parameter change fundamentally alters the therapeutic mechanism, leveraging IgM's superior complement activation and opsonization capabilities while maintaining ease of administration as a single intravenous preparation

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent applies the principle of local quality by enriching the immunoglobulin preparation specifically in IgM (10-40% of total immunoglobulin content) rather than using a uniform distribution of antibody types. This localized enrichment of specific immunoglobulin quality provides enhanced complement activation and pathogen neutralization while maintaining overall treatment simplicity

Inventive Principle:

Principle #3Local quality

3Reliability

If IgM-enriched immunoglobulin preparation is used, then complement activation and opsonization are enhanced, but the preparation must be plasma-derived and unmodified

Engineering Contradiction:

Improvecomplement activationVSAvoidpreparation complexity

Core Design Contradiction:

ReliabilityVSEase of manufacture

Solution Approach 1:

The patent extracts and enriches IgM from human plasma through fractionation processes, obtaining a preparation with 10-40% IgM content. This extraction approach preserves the natural structure and activity of IgM for complement activation while removing unnecessary components, achieving enhanced reliability without requiring complex chemical modification

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The patent changes the manufacturing parameter from chemically modified to unmodified plasma-derived preparation. This parameter change preserves the native structure of IgM molecules, maintaining their full complement activation capability while simplifying the manufacturing process by eliminating chemical modification steps

Inventive Principle:

Principle #35Parameter changes

4Adaptability or versatility

If patient selection is not optimized, then treatment can be applied broadly, but the benefit is diluted across all patients including those who would not respond

Engineering Contradiction:

Improvetreatment applicabilityVSAvoidtreatment benefit

Core Design Contradiction:

Adaptability or versatilityVSReliability

Solution Approach 1:

The patent implements feedback-based patient selection using biomarker assessment (CRP, PCT, IgM, IgG, IgA levels) to identify patients most likely to benefit from IgM-enriched immunoglobulin treatment. This feedback mechanism ensures treatment is directed to patients with specific inflammatory profiles and immunoglobulin deficiencies, maximizing treatment benefit while maintaining broad applicability to sCAP patients meeting the biomarker criteria

Inventive Principle:

Principle #23Feedback

Data Source

PatentUS12186391B2Treatment of severe community acquired pneumonia

Publication Date: 2025.01.07 BIOTEST-SERUM-INSTITUT GMBH

AI summary

The present invention provides for a new therapeutic tools capable of treating infectious diseases, in particular, a new pharmaceutical composition comprising an IgM-enriched immunoglobulin preparation for use in the adjunctive treatment of severe Community Acquired Pneumonia (sCAP).